Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Magy Onkol. 2012 Mar;56(1):38-49. doi: MagyOnkol.2012.56.1.38. Epub 2012 Jan 15.

[EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance].

[Article in Hungarian]

Author information

  • 1Semmelweis Egyetem Pulmonol√≥giai Klinika, Budapest, Hungary. drmoldvay@hotmail.com

Abstract

Tailored therapy in lung cancer is one of the most exciting fields in translational research and also a nice example of fruitful collaboration between pulmonologists, clinical oncologists, pathologists and molecular biologists. This article, through a dialogue between a pathologist-clinician and a molecular biologist-pharmacologist, gives an overview about the most important questions on molecular targeted therapy in clinical practice, especially, EGFR-TKI treatment, EGFR activating mutations, as well as primary and acquired resistance.

PMID:
22403761
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Hungarian Oncological Association
    Loading ...
    Write to the Help Desk